Bridgebio Oncology Therapeutics, Inc. (BBOT)
A forensic read on Bridgebio Oncology Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Bridgebio Oncology Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 13.6, placing it in the Grey zone. 1 forensic signal was flagged in its latest SEC filings, led by share count (stock split).
What the filings flag
Key fundamentals
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bridgebio Oncology Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?
Generate the AI investment read →No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.